A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Åsberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression.
The study has not yet been published. But MindBio’s CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was “in front of the curve in microdosing research.”
Ahh. I love to see when Coffee outperforms something that’s supposed to be stronger.
Coffee is relatively cheap and abundant; and still very abundant even if you are someone who chooses to pay a little more (Buying properly verified fair trade is a “good person” move.) to ensure that coffee growers get fair compensation.
